Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (13)

2016

  1. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

    Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400

2010

  1. Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors

    Journal of Biological Chemistry, Vol. 285, Núm. 15, pp. 11714-11729

2004

  1. Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: Synthesis of new transporter inhibitors as tools for this study

    British Journal of Pharmacology, Vol. 141, Núm. 3, pp. 457-467

2001

  1. Synthesis and structure-activity relationships of a new model of arylpiperazines. 5. Study of the physicochemical influence of the pharmacophore on 5-HT1A/α1-adrenergic receptor affinity: Synthesis of a new derivative with mixed 5-HT1A/D2 antagonist properties

    Journal of Medicinal Chemistry, Vol. 44, Núm. 2, pp. 186-197

1999

  1. Benzimidazole derivatives. 2. Synthesis and structure-activity relationships of new azabicyclic benzimidazole-4-carboxylic acid derivatives with affinity for serotoninergic 5-HT3 receptors

    Journal of Medicinal Chemistry, Vol. 42, Núm. 24, pp. 5020-5028

  2. Benzimidazole derivatives. Part 1: Synthesis and structure-activity relationships of new benzimidazole-4-carboxamides and carboxylates as potent and selective 5-HT4 receptor antagonists

    Bioorganic and Medicinal Chemistry, Vol. 7, Núm. 11, pp. 2271-2281

  3. Design and synthesis of 2-[4-[4-(m-(ethylsulfonamido)-phenyl)piperazin- 1-yl]butyl]-1,3-dioxoperhydropyrrolo[1,2c]imidazole (EF-7412) using neural networks. A selective derivative with mixed 5-HT(1A)/D2 antagonist properties

    Bioorganic and Medicinal Chemistry Letters, Vol. 9, Núm. 12, pp. 1679-1682

  4. Synthesis and structure-activity relationships of a new model of arylpiperazines 4. 1-[ω-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene)- 2,5-pyrrolidinediones and -3-(9h-fluoren-9-ylidene)-2,5-pyrrolidinediones: Study of the steric requirements of the terminal amide fragment on 5-HT(1A) affinity/selectivity

    Journal of Medicinal Chemistry, Vol. 42, Núm. 1, pp. 36-49

1998

  1. 1-[ω-(4-arylpiperazin-1-yl)alkyl]-3-diphenylmethylene-2,5-pyrrolidinediones as 5-HT(1A) receptor ligands: Study of the steric requirements of the terminal amide fragment on 5-HT(1A) affinity/selectivity

    Bioorganic and Medicinal Chemistry Letters, Vol. 8, Núm. 6, pp. 581-586

  2. Preclinical pharmacology of B-20991, a 5-HT(1A) receptor agonist with anxiolytic activity

    European Journal of Pharmacology, Vol. 344, Núm. 2-3, pp. 127-135

1996

  1. Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1,3- dioxoperhydroimidazo[1,5-a]pyridine: A selective 5-HT(1A) receptor agonist

    Journal of Medicinal Chemistry, Vol. 39, Núm. 22, pp. 4439-4450

1995

  1. α1-Adrenoceptor Reagents. Synthesis of Some 5,6,11,11α-Tetrahydro-1H-imidazo[1’,5’: 1,6]pyrido and 5,6,11,11b-Tetrahydro-1H-imidazo-[l’,5’: 1,2] pyrido [3,4-b] indole-1,3(2H)-diones

    Chemical and Pharmaceutical Bulletin, Vol. 43, Núm. 6, pp. 941-946

1994

  1. Reaction of 6-Hydroxy tetrahydro-β-carboline-3-carboxylic Acids with Isocyanates and Isothiocyanates

    Chemical and Pharmaceutical Bulletin, Vol. 42, Núm. 10, pp. 2108-2112